Ineffective skin wound healing is a significant source of morbidity and mortality. Roughly 6.5 million Americans experience chronically open wounds and the cost of treating these wounds numbers in the billions of dollars annually. In contrast, robust wound healing can lead to the development of either hypertrophic scarring or keloidosis, both of which can cause discomfort and can be cosmetically undesirable. Appropriate wound healing requires the interplay of a variety of factors, including the skin, the local microenvironment, the immune system, and the external environment. When these interactions are perturbed, wounds can be a nidus for infection, which can cause them to remain open an extended period of time, or can scar excessively. Interleukin-2, a cytokine that directs T-cell expansion and phenotypic development, appears to play an important role in wound healing. The best-studied role for Interleukin-2 is in influencing T-cell development. However, other cell types, including fibroblasts, the skin cells responsible for closing wounds, express the Interleukin-2 receptor, and therefore may respond to Interleukin-2. Studies have shown that treatment with Interleukin-2 can improve the strength of healed skin, which implicates Interleukin-2 in the wound healing process. Furthermore, diseases that involve impaired wound healing, such as diabetes and systemic lupus erythematosus, have been linked to deficiencies in Interleukin-2 or defects Interleukin-2-receptor signaling. The focus of this review is to summarize the current understanding of the role of Interleukin-2 in wound healing, to highlight diseases in which Interleukin-2 and its receptor may contribute to impaired wound healing, and to assess Interleukin-2-modulating approaches as potential therapies to improve wound healing.
SenCKGordilloGMRoySKirsnerRLambertLHuntTKGottrupFGurtnerGCLongakerMT. Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen2009; 17: 763–71.
2.
KhalilHCullenMChambersHCarrollMWalkerJ. Elements affecting wound healing time: An evidence based analysis. Wound Repair Regen2015; 23: 550–6.
3.
Wound dressings market (traditional wound dressings: wound closure products, basic wound care, anti-infective dressings; & advanced wound dressings: films, foams, hydrofiber, hydrocolloids, hydrogels, collagen, alginates) – global industry analysis, size, share, growth, trends, and forecast, 2014-2020. [press release]. Available from: http://www.transparencymarketresearch.com/wound-dressing-market.html.
4.
GauglitzGGKortingHCPavicicTRuzickaTJeschkeMG. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med2011; 17: 113–25.
5.
StebbinsWGGusevJHigginsHW2ndNelsonAGovindarajuluUNeelV. Evaluation of patient satisfaction with second intention healing versus primary surgical closure. J Am Acad Dermatol2015; 73: 865–7 e1.
6.
ReinholzMPoetschkeJSchwaigerHEppleARuzickaTGauglitzGG. The dermatology life quality index as a means to assess life quality in patients with different scar types. J Eur Acad Dermatol Venereol2015; 29: 2112–9.
7.
DiegelmannRFEvansMC. Wound healing: an overview of acute, fibrotic and delayed healing. Front Biosci2004; 9: 283–9.
8.
BroughtonG2ndJanisJEAttingerCE. The basic science of wound healing. Plast Reconstr Surg2006; 117(7 Suppl): 12S–34S.
9.
LopezNCerveroSJimenezMJSanchezJF. Cellular characterization of wound exudate as a predictor of wound healing phases. Wounds2014; 26: 101–7.
10.
LeoniGNeumannPASumaginRDenningTLNusratA. Wound repair: role of immune-epithelial interactions. Mucosal Immunol2015; 8: 959–68.
11.
EmingSAMartinPTomic-CanicM. Wound repair and regeneration: mechanisms, signaling, and translation. Sci Transl Med2015; 6: 1–16.
12.
FuRHWeinsteinALChangMMArgenzianoMAschermanJARohdeCH. Risk factors of infected sternal wounds versus sterile wound dehiscence. J Surg Res2016; 200: 400–7.
13.
OwensPLBarrettMLRaetzmanSMaggard-GibbonsMSteinerCA. Surgical site infections following ambulatory surgery procedures. JAMA2014; 311: 709–16.
WolframDTzankovAPulzlPPiza-KatzerH. Hypertrophic scars and keloids – a review of their pathophysiology, risk factors, and therapeutic management. Dermatol Surg2009; 35: 171–81.
16.
ToulonABretonLTaylorKRTenenhausMBhavsarDLaniganCRudolphRJamesonJHavranWL. A role for human skin-resident T cells in wound healing. J Exp Med2009; 206: 743–50.
KomoriHKWitherdenDAKellyRSendaydiegoKJamesonJMTeytonLHavranWL. Cutting edge: dendritic epidermal gammadelta T cell ligands are rapidly and locally expressed by keratinocytes following cutaneous wounding. J Immunol2012; 188: 2972–6.
19.
LiaoWLinJXWangLLiPLeonardWJ. Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages. Nat Immunol2011; 12: 551–9.
20.
LinJXLeonardWJ. The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene2000; 19: 2566–76.
21.
LinJXLeonardWJ. Signaling from the IL-2 receptor to the nucleus. Cytokine Growth Factor Rev1997; 8: 313–32.
22.
LanRYSelmiCGershwinME. The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2). J Autoimmun2008; 31: 7–12.
23.
GranucciFFeauSAngeliVTrotteinFRicciardi-CastagnoliP. Early IL-2 production by mouse dendritic cells is the result of microbial-induced priming. J Immunol2003; 170: 5075–81.
24.
ZhuJPaulWE. CD4 T cells: fates, functions, and faults. Blood2008; 112: 1557–69.
25.
LiaoWLinJXLeonardWJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity2013; 38: 13–25.
26.
NelsonBHWillerfordDM. Biology of the interleukin-2 receptor. Adv Immunol1998; 70: 1–82.
27.
KhanSHMartinMDStarbeck-MillerGRXueHHHartyJTBadovinacVP. The timing of stimulation and IL-2 signaling regulate secondary CD8 T cell responses. PLoS Pathog2015; 11: e1005199–e1005199.
28.
WangLHKirkenRAErwinRAYuCFarrarWL. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response. J Immunol1999; 162: 3897–904.
29.
OrtonRJSturmOEVyshemirskyVCalderMGilbertDRKolchW. Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway. Biochem J2005; 392(Pt 2): 249–61.
30.
DownwardJ. Targeting RAS and PI3K in lung cancer. Nat Med2008; 14: 1315–6.
31.
DuPageMBluestoneJA. Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease. Nat Rev Immunol2016; 16: 149–63.
32.
GoldsteinJDPerolLZaragozaBBaeyensAMarodonGPiaggioE. Role of cytokines in thymus- versus peripherally derived-regulatory T cell differentiation and function. Front Immunol2013; 4: 155–155.
33.
LongSACerosalettiKWanJYHoJCTatumMWeiSSchillingHGBucknerJH. An autoimmune-associated variant in PTPN2 reveals an impairment of IL-2R signaling in CD4(+) T cells. Genes Immun2011; 12: 116–25.
34.
RubinLAKurmanCCFritzMEBiddisonWEBoutinBYarchoanRNelsonDL. Souble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J Immunol1985; 135: 3172–7.
35.
KondoNKondoSShimizuAHonjoTHamuroJ. A soluble ‘Anchorminus' interleukin 2 receptor suppresses in vitro interleukin 2-mediated immune responses. Immunol Lett1988; 19: 299–308.
36.
JacquesYLe MauffBBoeffardFGodardASoulillouJP. A soluble interleukin 2 receptor produced by a normal alloreactive human T cell clone binds interleukin 2 with low affinity. J Immunol1987; 139: 2308–16.
37.
SymonsJAWoodNCDi GiovineFSDuffGW. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition. J Immunol1988; 141: 2612–8.
38.
FurtadoGCde LafailleMACKutchukhidzeNLafailleJJ. Interleukin 2 signaling is required for CD4+regulatory T cell function. J Exp Med2002; 196: 851–7.
39.
RayJPStaronMMShyerJAHoPCMarshallHDGraySMLaidlawBJArakiKAhmedRKaechSMCraftJ. The interleukin-2-mTORc1 kinase axis defines the signaling, differentiation, and metabolism of T helper 1 and follicular B helper T cells. Immunity2015; 43: 690–702.
40.
DoomsHWolslegelKLinPAbbasAK. Interleukin-2 enhances CD4+ T cell memory by promoting the generation of IL-7R alpha-expressing cells. J Exp Med2007; 204: 547–57.
41.
BusseDde la RosaMHobigerKThurleyKFlossdorfMScheffoldAHoferT. Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments. Proc Natl Acad Sci U S A2010; 107: 3058–63.
42.
LeclercqGDe SmedtMTisonBPlumJ. Preferential proliferation of T cell receptor V gamma 3-positive cells in IL-2 stimulated fetal thymocytes. J Immunol1990; 145: 3992–7.
43.
Kjeldsen-KraghJQuayleAJSkalheggBSSioudMForreO. Selective activation of resting human γδ T lymphocytes by interleukin-2. Eur J Immunol1993; 23: 2092–9.
44.
OrsiniDLMKooyYMCVan Der TolMAStruykLVan Den ElsenP. T-cell receptor usage of interleukin-2-responsive peripheral gd T cells. Immunology1995; 86: 385–91.
45.
Litwin SD. Product: proleukin (aldesleukin), proleukin, interleukin-2 (IL-2). Silver Sping, MD: Food and Drug Administration, 1998.
46.
McDermottDFReganMMAtkinsMB. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials. Clin Genitourin Cancer2006; 5: 114–9.
47.
AtkinsMBLotzeMTDutcherJPFisherRIWeissGMargolinKAbramsJSznolMParkinsonDHawkinsMParadiseCKunkelLRosenbergSA. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol1999; 17: 2105–16.
ShiVYTranKPatelFLeventhalJKoniaTFungMAWilkenRGarciaMSFitzmauriceSDJooJMonjabezAMBurrallBAKingBMartinezSChristensenSDMaverakisE. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series. J Am Acad Dermatol2015; 73: 645–54.
50.
WooKY. Exploring the effects of pain and stress on wound healing. Adv Wound Care2012; 25: 38–44.
Kowal-VernAWalengaJMHoppensteadtDSharp-PucciMGamelliRL. Interleukin-2 and interleukin-6 in relation to burn wound size in the acute phase of thermal injury. J Am Coll Surg1994; 178: 357–62.
53.
Mikhal'chikEVPiterskayaJABudkevichLYPen'kovLYFacchianoADe LucaC. Comparative study of cytokine content in the plasma and wound exudate from children with severe burns. Bull Exp Biol Med2009; 148: 771–5.
54.
CurrieHNLoosMSVranaJADraganKBoydJW. Spatial cytokine distribution following traumatic injury. Cytokine2014; 66: 112–8.
55.
HanAACurrieHNLoosMSVranaJAFabyanicEBPredigerMSBoydJW. Spatiotemporal phosphoprotein distribution and associated cytokine response of a traumatic injury. Cytokine2016; 79: 12–22.
SakakibaraSInouyeKShudoKKishidaYKobayashiYProckopDJ. Synthesis of (Pro-Hyp-Gly)n of defined molecular weights. Evidence for the stabilization of collagen triple helix by hydroxyproline. Biochem Biophys Acta1973; 303: 198–202.
58.
ByrdVMBallardDWMillerGGThomasJW. Fibroblast growth factor-1 (FGF-1) enhances IL-2 production and nuclear translocation of NF-kB in FGF receptor-bearing Jurkat T cells. J Immunol1999; 162: 5853–9.
59.
OzawaATadaHTamaiRUeharaAWatanabeKYamaguchiTShimauchiHTakadaHSugawaraS. Expression of IL-2 receptor B and Γ chains by human gingival fibroblasts and up-regulation of adhesion to neutrophils in response to IL-2. J Leukocyte Biol2003; 74: 352–9.
60.
CorrigallVMArastuMKhanSShahCFifeMSmeetsTTakPPanayiGS. Functional IL-2 receptor B (CD122) and Γ (CD132) chains are expressed by fibroblast-like synoviocytes: activation by IL-2 stimulates monocyte chemoattractant protein-1 production. J Immunol2001; 166: 4141–7.
61.
KangRTangDLotzeMTZeh IiiHJ. Autophagy is required for IL-2-mediated fibroblast growth. Exp Cell Res2013; 319: 556–65.
62.
SerbanAIStancaLGeicuOIMunteanuMCDinischiotuA. RAGE and TGF-beta1 cross-talk regulate extracellular matrix turnover and cytokine synthesis in AGEs exposed fibroblast cells. PLoS One2016; 11: e0152376–e0152376.
63.
BreslinRJBarbulAKupperTSKnud-HansenJWasserkrugHLEfronG. Generation of an anti-interleukin-2 factor in healing wounds. Arch Surg1988; 123: 305–8.
64.
BoymanOSprentJ. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol2012; 12: 180–90.
65.
BoymanOKoliosAGARaeberME. Modulation of T cell responses by IL-2 and IL-2 complexes. Clin Exp Rheumatol2015; 33(Suppl. 92): S54–S7.
66.
LehmannPHomeyB. Clinic and pathophysiology of photosensitivity in lupus erythematosus. Autoimmun Rev2009; 8: 456–61.
67.
KuhnASontheimerRD. Cutaneous lupus erythematosus: molecular and cellular basis of clinical findings. Curr Dir Autoimmun2008; 10: 119–40.
68.
RobinsonESWerthVP. The role of cytokines in the pathogenesis of cutaneous lupus erythematosus. Cytokine2015; 73: 326–34.
69.
HanssenADCabanelaMEMichetCJ. Hip arthroplasty in patients with systemic lupus erythematosus. J Bone Joint Surg1987; 69: 807–14.
70.
HeydemannA. The super super-healing MRL mouse strain. Front Biol2012; 7: 522–38.
71.
PetittoJMHuangZLoJBeckRDRinkerCHarteminkDA. Relationship between the development of autoimmunity and sensorimotor gating in MRL-lpr mice with reduced IL-2 production. Neurosci Lett2002; 328: 304–8.
72.
KenchJARussellDMFadokVAYoungSKWorthenGSJones-CarsonJHensonJEHensonPMNemazeeD. Aberrant wound healing and TGF-β production in the autoimmune-prone MRL/+ mouse. Clin Immunol1999; 92: 300–10.
73.
KatsiariCGTsokosGC. Transcriptional repression of interleukin-2 in human systemic lupus erythematosus. Autoimmun Rev2006; 5: 118–21.
74.
CarneiroJRMFuziiHTKayserCAlbertoFLSoaresFASatoEIAndradeLEC. IL-2, IL-5, TNF-α and IFN-γ mRNA expression in epidermal keratinocytes of systemic lupus erythematosus skin lesions. Clinics2011; 66: 77–82.
75.
SolomouEEJuangYGourleyMFKammerGMTsokosGC. Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J Immunol2011; 166: 4216–22.
76.
Linker-IsraeliMBakkeACKitridouRCGendlerSGillisSHorwitzDA. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol1983; 130: 2651–5.
77.
Alcocer-VarelaJAlarcon-SegoviaD. Longitudinal study of the production of and cellular response to interleukin-2 in patients with systemic lupus erythematosus. Rheumatol Int1995; 15: 57–63.
78.
MiyagiJMinatoNSumiyaMKasaharaTKanoS. Two typesof antibodies inhibiting interleukin-2 production by normal lymphocytes in patients with systemic lupus erythematosus. Arth Rheum1989; 32: 1356–64.
79.
WofsyDMurphyEDRothsRBDauphineeMJKipperSBTalalN. Deficient Interleukin 2 activity in MRL/Mp and C57BL6/J mice bearing the LPR gene. J Exp Med1981; 154: 1671–80.
80.
SawadaSHashimotoHIijmaSTokanoYMatsukawaYTakeiMIshikawaHKangHTomuraKMitamuraKHashimotoSObaraT. Increased soluble Il-2 receptor in serum of patients with systemic lupus erythematosus. Clin Rheumatol1993; 12: 204–9.
81.
IannuzziMCRybickiBATeirsteinAS. Sarcoidosis. N Engl J Med2007; 357: 2153–65.
82.
BuechnerSAWinkelmannRKBanksPM. T-cell subsets in cutaneous sarcoidosis. Arch Dermatol1983; 119: 728–32.
SaltiniCSpurzemJRLeeJJPinkstonPCrystalRG. Spontaneous release of interleukin 2 by lung T lymphocytes in active pulmonary sarcoidosis is primarily from the Leu3+DR+ T cell subset. J Clin Invest1986; 77: 1962–70.
85.
PinkstonPBittermanPBCrystalRG. Spontaneous release of interleukin-2 by lung T lymphocytes in active pulmonary sarcoidosis. N Engl J Med1983; 308: 793–800.
86.
PinkstonPSaltiniCMuller-QuernheimJCrystalRG. Corticosteroid therapy suppresses spontaneous interleukin 2 release and spontaneous proliferation of lung T lymphocytes of patients with active pulmonary sarcoidosis. J Immunol1987; 139: 755–60.
87.
SuRNguyenMTAgarwalMRKirbyCNguyenCPRamsteinJDarnellEPGomezADHoMWoodruffPGKothLL. Interferon-inducible chemokines reflect severity and progression in sarcoidosis. Respir Res2013; 14: 1–9.
88.
GundlachEHoffmannMMPrasseAHeinzelmannSNessT. Interleukin-2 receptor and angiotensin-converting enzyme as markers for ocular sarcoidosis. PLoS One2016; 11: e0147258–e0147258.
89.
VorselaarsADvan MoorselCHZanenPRuvenHJClaessenAMvan Velzen-BladHGruttersJC. ACE and sIL-2R correlate with lung function improvement in sarcoidosis during methotrexate therapy. Respir Med2015; 109: 279–85.
90.
ForbesJMCooperME. Mechanisms of diabetic complications. Physiol Rev2013; 93: 137–88.
91.
AckermannPWHartDA. Influence of comorbidities: neuropathy, vasculopathy, and diabetes on healing response quality. Adv Wound Care2013; 2: 410–21.
92.
LoweCECooperJDBruskoTWalkerNMSmythDJBaileyRBourgetKPlagnolVFieldSAtkinsonMClaytonDGWickerLSToddJA. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet2007; 39: 1074–82.
93.
van BelleTLCoppietersKTvon HerrathMG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev2011; 91: 79–118.
94.
GargGTylerJRYangJHCutlerAJDownesKPekalskiMBellGLNutlandSPeakmanMToddJAWickerLSTreeTI. Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function. J Immunol2012; 188: 4644–53.
95.
LongSAReickMSandaSBollykyJBSamuelsPLGolandRAhmannARabinovitchAAggarwalSPhippardDTurkaLAEhlersMRBianchinePJBoyleKDAdahSABluestoneJABucknerJHGreenbaumCJ. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs b-cell function. Diabetes2012; 61: 2340–8.
96.
HartemannABensimonGPayanCAJacqueminetSBourronONicolasNFonfredeMRosenzwajgMBernardCKlatzmannD. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diab Endocrinol2013; 1: 295–305.
97.
LongSACerosalettiKBollykyPLTatumMShillingHZhangSZhangZPihokerCSandaSGreenbaumCBucknerJH. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4+CD25+ regulatory T-cells of type 1 diabetic subjects. Diabetes2010; 59: 407–15.
98.
LagmanMLyJSaingTKaur SinghMVera TudelaEMorrisDChiPTOchoaCSathananthanAVenketaramanV. Investigating the causes for decreased levels of glutathione in individuals with type II diabetes. PLoS One2015; 10: e0118436–e0118436.
99.
CaiBZhangJZhangMLiLFengWAnZWangL. Micro-inflammation characterized by disturbed Treg/Teff balance with increasing sIL-2R in patients with type 2 diabetes. Exp Clin Endocrinol Diab2013; 121: 214–9.
100.
PereiraFOFrodeTSMedeirosYS. Evaluation of tumour necrosis factor alpha, interleukin-2 soluble receptor, nitric oxide metabolites, and lipids as inflammatory markers in type 2 diabetes mellitus. Mediat Inflamm2006; 2006: 39062–39062.
101.
Grinberg-BleyerYBaeyensAYouSElhageRFourcadeGGregoireSCagnardNCarpentierWTangQBluestoneJChatenoudLKlatzmannDSalomonBLPiaggioE. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med2010; 207: 1871–8.
102.
FloresRRZhouLRobbinsPD. Expression of IL-2 in beta cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabetes through activation of FoxP3-positive regulatory T cells. Gene Ther2014; 21: 715–22.
103.
JohnsonMCGarlandALNicolsonSCLiCSamulskiRJWangBTischR. B-cell-specific IL-2 therapy increases islet Foxp3+Treg and suppresses type 1 diabetes in NOD mice. Diabetes2013; 62: 3775–84.
104.
Diaz-de-DuranaYLauJKneeDFilippiCLondeiMMcNamaraPNasoffMDiDonatoMGlynneRHermanAE. IL-2 immunotherapy reveals potential for innate beta cell regeneration in the non-obese diabetic mouse model of autoimmune diabetes. PLoS One2013; 8: e78483–e78483.
105.
BaeyensAPerolLFourcadeGCagnardNCarpentierWWoytschakJBoymanOHartemannAPiaggioE. Limitations of IL-2 and rapamycin in immunotherapy of type 1 diabetes. Diabetes2013; 62: 3120–31.
106.
NunanRHardingKGMartinP. Clinical challenges of chronic wounds: searching for an optimal animal model to recapitulate their complexity. Dis Model Mech2014; 7: 1205–13.
107.
FrangogiannisNG. Regulation of the inflammatory response in cardiac repair. Circ Res2012; 110: 159–73.
108.
CaoCMXiaQTuJChenMWuSWongTM. Cardioprotection of interleukin-2 is mediated via kappa-opioid receptors. J Pharmacol Exp Ther2004; 309: 560–7.
109.
BouchentoufMWilliamsPFornerKACuerquisJMichaudVParadisPSchiffrinELGalipeau. Interleukin-2 enhances angiogenesis and preserves cardiac function following myocardial infarction. Cytokine2011; 56: 732–8.
110.
KochMSavvatisKScheelerMDhayatSBonaventuraKPohlTRiadABulfone-PausSSchultheissHPTschopeC. Immunosuppression with an interleukin-2 fusion protein leads to improved LV function in experimental ischemic cardiomyopathy. Int Immunopharmacol2010; 10: 207–12.
111.
ZengZYuKChenLLiWXiaoHHuangZ. Interleukin-2/anti-interleukin-2 immune complex attenuates cardiac remodeling after myocardial infarction through expansion of regulatory T cells. J Immunol Res2016; 2016: 8493767–8493767.
112.
VialTDescotesJ. Clinical toxicity of interleukin-2. Drug Saf1992; 7: 417–33.
113.
KragelAHTravisWDSteisRGRosenbergSARobertsWC. Myocardial or acute myocardial infarction associated with interleukin-2 therapy for cancer. Cancer1990; 66: 1513–6.
114.
BlumASclarovskySRehaviaEShohatB. Levels of T-lymphocytes subpopulations, interleukin-1b, and soluble interleukin-2 receptor in acute myocardial infarction. Am Heart J1994; 127: 1226–30.
115.
ZhangDWangSGuanYWangLXieWLiNZhaoPSuG. Effect of oral atorvastatin on CD4+CD25+ regulatory T cells, FoxP3 expression, and prognosis in patients with ST-segment elevated myocardial infarction before primary percutaneous coronary intervention. J Cardiovasc Pharmacol2011; 57: 536–41.
